Urinary Bladder Neoplasms: all 1,649 studies

Page 5 of 17. Open to participants first (427), then studies with results posted, then the rest; newest registration first within each.

• The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruitingNCT04075305
• Prospective Sample Collection for Cancer of BladderRecruitingNCT03973671
• UroX Biomarker Bladder Cancer StudyRecruitingNCT03973307
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyRecruitingNCT03844256Phase 1/2
• Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsRecruitingNCT03740256Phase 1
• Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder CancerRecruitingNCT03664869Phase 3
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
• Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/BiomarkersRecruitingNCT03413982
• Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder CancerRecruitingNCT03379909Phase 2
• SArcopenia, Mobility, PHYsical Activity and Post-operative Risk of Bladder Carcinoma in the ElderlyRecruitingNCT03362801Not applicable
• Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery ProtocolRecruitingNCT03216525Phase 3
• Measuring Surgical Recovery After Radical CystectomyRecruitingNCT03193970
• A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder CancerRecruitingNCT03193541
• A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder CancerRecruitingNCT03193515
• Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal NeobladderRecruitingNCT03108196Not applicable
• Image-Guided Gynecologic BrachytherapyRecruitingNCT02993900Not applicable
• Blue Light Cystoscopy With Cysview® RegistryRecruitingNCT02660645
• Decipher Genomics Resource for Intelligent DiscoveryEnrolling by invitationNCT02609269
• Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer TissueRecruitingNCT02379429
• Cancer Experience Registry (CER) for Cancer Patients and CaregiversRecruitingNCT02333604
• A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney.RecruitingNCT02186925
• Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
• Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial CancerRecruitingNCT01050504
• Evaluation of Non-Invasive Assays for the Detection of Urothelial CancerRecruitingNCT00872495
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseRecruitingNCT00026884
• Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruitingNCT00001823
• A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerCompletedNCT06331299Phase 3Results posted
• Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)Active, not recruitingNCT05696444Not applicableResults posted
• Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder CancerCompletedNCT05600322Phase 3Results posted
• Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder CancerTerminatedNCT05581589Phase 2Results posted
• Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or BladderCompletedNCT05512377Phase 2Results posted
• A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid TumoursTerminatedNCT05397171Phase 1/2Results posted
• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2Results posted
• Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)CompletedNCT05259696Phase 1/2Results posted
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerActive, not recruitingNCT05243550Phase 3Results posted
• Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedNCT05136898Phase 3Results posted
• The Personal Patient Profile Decision Support for Patients With Bladder CancerCompletedNCT05033067Not applicableResults posted
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results posted
• Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsTerminatedNCT04985604Phase 2Results posted
• Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial CancerTerminatedNCT04936230Phase 2Results posted
• A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the BladderCompletedNCT04919512Phase 2Results posted
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedNCT04902040Phase 1/2Results posted
• Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBCCompletedNCT04897763Early Phase 1Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then AvelumabTerminatedNCT04887831Phase 2Results posted
• Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)TerminatedNCT04871529Phase 2Results posted
• A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMACompletedNCT04822350Results posted
• Radiogenomics of Muscle Invasive Bladder CancerTerminatedNCT04806334Not applicableResults posted
• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder CancerTerminatedNCT04779489Not applicableResults posted
• LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint InhibitorsTerminatedNCT04690699Phase 1/2Results posted
• A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerTerminatedNCT04688931Phase 3Results posted
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyActive, not recruitingNCT04640623Phase 2Results posted
• Behavioral Dietary Intervention for the Improvement of Bladder Cancer SurvivorshipCompletedNCT04548193Phase 1Results posted
• Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder TumorsCompletedNCT04525131Phase 2Results posted
• Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical CystectomyCompletedNCT04502095Phase 4Results posted
• Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder CancerCompletedNCT04496219Phase 2Results posted
• Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)CompletedNCT04492007Not applicableResults posted
• AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder CancerTerminatedNCT04430036Phase 2Results posted
• Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder CancerActive, not recruitingNCT04386746Phase 2Results posted
• Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesCompletedNCT04383938Phase 1/2Results posted
• Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder CancerCompletedNCT04383743Phase 2Results posted
• FITBIT Study on Mobility and Readmissions After Radical CystectomyCompletedNCT04314778Not applicableResults posted
• TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersCompletedNCT04306900Phase 1Results posted
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
• A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerCompletedNCT04209114Phase 3Results posted
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedNCT04197986Phase 3Results posted
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT04172675Phase 2Results posted
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerActive, not recruitingNCT04165317Phase 3Results posted
• A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)TerminatedNCT04149574Phase 3Results posted
• Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE StudyTerminatedNCT04066894Phase 2Results posted
• Recovery Support for Bladder Cancer Patients and CaregiversCompletedNCT04055311Not applicableResults posted
• Role of FDG-PET CT in the Management of Muscle Invasive Bladder CancerCompletedNCT04053101Results posted
• Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer PatientsActive, not recruitingNCT04046094Phase 1/2Results posted
• Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder CancerTerminatedNCT04039867Phase 2Results posted
• 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical CystectomyCompletedNCT04018053Early Phase 1Results posted
• Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT04004221Phase 2Results posted
• Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/2Results posted
• Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerActive, not recruitingNCT03978624Phase 2Results posted
• CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder CancerActive, not recruitingNCT03933826Results posted
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)Active, not recruitingNCT03924895Phase 3Results posted
• Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder CancerCompletedNCT03892642Phase 1/2Results posted
• TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersCompletedNCT03884556Phase 1Results posted
• Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
• A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerCompletedNCT03785925Phase 2Results posted
• Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by SurgeryActive, not recruitingNCT03757949Phase 3Results posted
• Avelumab and Radiation in Muscle-Invasive Bladder CancerTerminatedNCT03747419Phase 2Results posted
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive, not recruitingNCT03732677Phase 3Results posted
• Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBCTerminatedNCT03719300Phase 2Results posted
• Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachCompletedNCT03702179Phase 2Results posted
• Evaluation of NanoDoce® in Participants With Urothelial CarcinomaCompletedNCT03636256Phase 1/2Results posted
• CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03628716Phase 2Results posted
• Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerCompletedNCT03617913Phase 2Results posted
• A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03606174Phase 2Results posted
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateActive, not recruitingNCT03582475Phase 1Results posted
• A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerCompletedNCT03558503Phase 2Results posted
• Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder SparingCompletedNCT03558087Phase 2Results posted
• Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerCompletedNCT03532451Phase 1Results posted
• A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTerminatedNCT03519256Phase 2Results posted
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
• A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder CancerTerminatedNCT03498196Phase 1/2Results posted

← Urinary Bladder Neoplasms overview